Sentiment Trading

Santhera Pharmaceuticals has partnered with Uniphar to distribute its Duchenne muscular dystrophy treatment AGAMREE in five Gulf Cooperation Council countries, starting with a named-patient program in Q1 2026.

Santhera Pharmaceuticals has expanded its global reach by signing an exclusive distribution agreement with Gen İlaç in Türkiye for its Duchenne muscular dystrophy treatment, AGAMREE.

Santhera Pharmaceuticals reported a year of transformation and growth in 2024, driven by the successful launch of AGAMREE, a groundbreaking treatment for Duchenne Muscular Dystrophy, and strategic financial management.